Answers are grounded in this paper and cite their sources.
Hypofractionated radiotherapy (HFRT) combined with immunochemotherapy holds promise for overcoming immune resistance in microsatellite‐stable (MSS) locally advanced rectal cancer (LARC). However, the mechanisms underlying its effects remain unclear. Using secretome profiling, ATAC‐seq, bulk and single‐cell RNA sequencing, we investigated how HFRT remodels the tumor immune microenvironment. APOC2 was induced by HFRT, and higher post‐treatment serum APOC2 levels were associated with pathologic complete response (pCR) to HFRT‐based neoadjuvant immunochemotherapy. Mechanistically, HFRT reduced ATF3 expression, relieving its repression of the APOC2 promoter and increasing tumor‐cell APOC2 secretion. APOC2 activated lipoprotein lipase, increased free fatty acid production, enhanced type I interferon signaling, and promoted the differentiation of Ly6A + inflammatory monocytes. These monocytes exhibit specialized MHC class I antigen‐presentation programs that bolster CD8 + T‐cell effector functions. Clinically, the APOC2 nomogram demonstrated consistent discriminative ability for pCR across the discovery and internal validation cohorts. Therapeutic supplementation with recombinant APOC2 or APOC2‐loaded nanoliposomes (APOC2@NL) sensitized murine tumors to HFRT plus PD‐1 blockade. These findings position APOC2 as a functional mediator between radiotherapy‐induced metabolism and antitumor immunity, offering a promising biomarker and a preclinical therapeutic proof of concept for LARC.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: